Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Subscribe To Our Newsletter & Stay Updated